Reed-Sternberg cells and the TNF family of receptors/ligands

Leukemia and Lymphoma

Volumn 27, Issue 3-4, 1997, Pages 195-204

  Clodi, Katharina ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CD30; CD30L; CD40; CdD0L; Fas; FasL; Hodgkin's disease; Reed Sternberg cell

Indexed keywords

CD30 ANTIGEN; CD40 ANTIGEN; FAS ANTIGEN; GLYCOPROTEIN GP 39; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CANCER SURVIVAL; DRUG RESEARCH; HODGKIN DISEASE; HUMAN; IMMUNOSURVEILLANCE; LIGAND BINDING; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BINDING; REED STERNBERG CELL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030777876     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709059676     Document Type: Review

References (124)

1. Urba, W. J. and Longo, D. L. (1992). Hodgkin's disease. N. Engl. J. Med., 326, 678-687.
2. Tesch, H. and Diehl, V. (1996). Hodgkin's disease: from basic science to clinical applications. Leukemia, 10, 74-77.
3. Poppema, S., Kaleta, J., Hepperle, B. and Visser, L. (1992) Biology of Hodgkin's disease. Ann. Oncol., 3 (suppl 4), 5-8.
4. Johnson, D., Lanahan, A., Buck, C. R., Sehgal, A., Morgan, C., Mercer, E., Bothwell, M. and Chao, M. (1986). Expression and structure of the human NGF receptor. Cell, 47, 545-554.
5. Smith, D. A., Davis, T., Anderson, D., Solam. L., Beckmann, M. P., Jerzy, R., Dower, S. K., Cosman, D. and Goodwin, R. G. (1990). A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science, 248, 1019-1023.
6. Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H., Gananga, T., Granger, G. A., Lentz, R., Raab, H., Kohr, W. J. and Goeddel, D. V. (1990). Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell, 61, 361-370.
7. Loetscher, H., Pan, Y. C., Lahm, H. W. and Lesslauer, W. (1990). Molecular cloning and expression on the human 55 kD tumor necrosis factor receptor. Cell, 61, 351-359.
8. Baens, M., Chaffanet, M., Cassiman, J. J., Van den Berghe, H. and Marynen, P. (1993). Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid. Genomics, 16, 214-218.
9. Camerini, D., Walz, G., Loenen, W. A., Borst, J. and Seed, B. (1991). The T-cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J. Immunol., 147, 3165-3169.
10. Stamenkovic, I., Clark, E. A. and Seed, B. (1989). A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J, 8, 1403-1410.
11. Durkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. and Stein, H. (1992). Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell, 68, 421-427.
12. Mallett, S., Fossum, S. and Barclay, A. N. (1990). Characterization of the MRC OX40 antigen of activated CD4 positive T-lymphocytes-a molecule related to nerve growth factor receptor, EMBO J, 9, 1063-1086.
13. Kwon, B. S. and Weissman, S. M. (1989). cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. U S A, 86, 1963-1967.
14. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y. and Nagata, S. (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233-243.
15. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., et al. (1992). Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem., 267, 10709-15.
16. Berberich, I., Shu, G., Siebelt, F., Woodgett, J. R., Kyriakis, J. M. and Clark, E. A. (1996). Cross-linking CD40 on B-cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. EMBO J, 15, 92-101.
17. Josimovic-Alasevic, O., Durkop, H., Schwarting, R., Backe, E., Stein, H. and Diamanstein, T. (1989). Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatnants and in serum by and enzyme-linked immunosorbent assay. Eur. J. Immunol., 19, 157-162.
18. Kohno, T., Brewer, M. T., Baker, S. L., Schwartz, P. E., King, M. W., Hale, K. K., Squires, C. H., Thompson, R. C. and Vannice, J. L. (1990). A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl. Acad. Sci. U S A, 87, 8331-8335.
19. Lantz, M., Gullberg, U., Nilsson, E. and Olsson, I. (1990). Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J. Clin. Invest., 86, 1396-1342.
20. Porteu, F. and Nathan, C. (1990). Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med., 172, 599-607.
21. Hintzen, R. Q., de Jong, R., Hack, C. E., Chamuleau, M., de Vries, E. F., ten Berge, I. J., Borst, J. and van Lier, R. A. (1991). A soluble form of the human T-cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex, J. Immunol., 147, 29-35.
22. Loenen, W. A., De Vries, E., Gravestein, L. A., Hintzen, R. Q., van Lier, R. A. and Borst, J. (1992). The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur. J. Immunol., 22, 447-455.
23. van Kooten, C., Gaillard, C., Galizzi, J. P., Hermann, P., Fossiez, F., Banchereau, J. and Blanchard, D. (1994). B-cells regulate expression of CD40 ligand on activated T-cells by lowering the mRNA level and through the release of soluble CD40. Eur. J. Immunol., 24, 787-792.
24. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J. and Mountz, J. D. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science, 263, 1759-1762.
25. Falini, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, L., Stirpe, F., Martelli, M. F. and Stein, H. (1995). CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood, 85, 1-14.
26. + tumors: a mechanism for evading immunosurveillance? Ann. Oncol., 7, 149 (abstr).
27. Owen-Schaub, L. B., Angelo, L. S., Radinsky, R., Ware, C. F., Gesner, T. G. and Bartos, D. P. (1995). Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer, 94, 1-8.
28. Bradshaw, R. A., Blundell, T. L., Lapatto, R., McDonald, N. Q. and Murray-Rust, J. (1993). Nerve growth factor revisited. Trends. Biochem. Sci., 18, 48-52.
29. Eide, F. F., Lowenstein, D. H. and Reichardt, L. F. (1993). Neurotrophins and their receptors-current concepts and implications for neurologic disease. Exp. Neurol., 121, 200-214.
30. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B. and Goeddel, D. V. (1984). Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature, 312, 724-729.
31. Old, L. J. (1985). Tumor necrosis factor (TNF). Science, 230, 630-632.
32. Beutler, B. and Cerami, A. (1986). Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature, 320, 584-588.
33. Gray, P. W., Aggarwal, B. B., Benton, C. V., Bringman, T. S., Henzel, W. J., Jarrett, J. A., Leung, D. W., Moffat, B., Ng, P., Svedersky, L. P., et al. (1984). Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature, 312, 721-724.
34. Aggarwal, B. B., Henzel, W. J., Moffat, B., Kohr, W. J. and Harkins, R. N. (1985). Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line, J. Biol. Chem., 260, 2334-2344.
35. Browning, J. L., Ngam-ek, A., Lawton, P., De Marinis, J., Tizard, R., Chow, E. P., Hession, C., O'Brine-Greco, B., Foley, S. F. and Ware, C. F. (1993). Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell, 72, 847-856.
36. Goodwin, R. G., Alderson, M. R., Smith, C. A., Armitage, R. J., Vanden Bos, T., Jerzy, R., Tough, T. W., Schoenborn, M. A., Davis-Smith, T., Hennen, K., et al. (1993). Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell, 73, 447-456.
37. Smith, C. A., Gruss, H. J., Davis, T., Anderson, D., Farrah, T., Baker, E., Sutherland, G. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., et al. (1993). CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell, 73, 1349-1360.
38. Armitage, R. J., Fanslow, W. C., Strockbine, L., Sato, T. A., Clifford, K.N., Macduff, B.M., Anderson, D. M., Gimpel, S.D., Davis-Smith, T., Maliszewski, C. R. et al. ( 1992). Molecular and biological characterization of a murine ligand for CD40. Nature, 357, 80-82.
39. Graf, D., Korthauer, U., Mages, H. W., Senger, G. and Kroczek, R. A. (1992). Cloning of TRAP, a ligand for CD40 on human T-cells. Eur. J. Immunol., 22, 3191-3194.
40. Francis, D. A., Karras, J. G., Ke, X. Y., Sen, R. and Rothstein, T. L. (1995). Induction of the transcription factors NF-kappa B, AP-1 and NF-AT during B-cell stimulation through the CD40 receptor. Int. Immunol., 7, 151-161.
41. Saiki, O., Tanaka, T., Wada, Y., Uda, H., Inoue, A., Katada, Y., Izeki, M., Iwata, M., Nunoi, H., Matsuda, I. et al. (1995). Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM. J. Clin. Invest., 95, 510-514.
42. Gauchat, J. F., Aubry, J. P., Mazzei, G., Life, P., Jomotte, T., Elson, G. and Botinefoy, J. Y. (1993). Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett, 315, 259-266.
43. Goodwin, R. G., Din, W. S., Davis-Smith, T., Anderson, D. M., Gimpel, S. D., Sato, T. A., Maliszewski, C. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. et al. (1993). Molecular cloning of a ligand for the inducible T-cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol., 23, 2631-2641.
44. Alderson, M. R., Smith, C. A., Tough, T. W., Davis-Smith, T., Armitage, R. J., Falk, B., Roux, E., Baker, E., Sutherland, G. R., Din, W. S. et al. (1994). Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol., 24, 2219-2227.
45. Ziegler, S. F., Bird, T. A., Schneringer, J. A., Schooley, K. A. and Baum, P. R. (1993). Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene, 8, 663-670.
46. + T-cells with homology to tumor necrosis factor. J. Exp. Med., 180, 757-762.
47. Suda, T., Takahashi, T., Golstein, P. and Nagata, S. (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75, 1169-1178.
48. Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F. and Lynch, D. H. (1995). Fas ligand mediates activation-induced cell death in human T-lymphocytes. J. Exp. Med., 181, 71-77.
49. Lynch, D. H., Watson, M. L., Alderson, M. R., Baum, P. R., Miller, R. E., Tough, T., Gibson, M., Davis-Smith, T., Smith, C. A., Hunter, K. et al (1994). The mouse Fasligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity, 1, 131-136.
50. Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T. and Nagata, S. (1994). Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell, 76, 969-976.
51. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A. and Goodwin, R. G. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-682.
52. Gruss, H. J. and Dower, S. K. (1995). Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood, 85, 3378-3404.
53. Baum, P. R., Gayle, R. B., Ramsdell, F., Srinivasan, S., Sorensen, R. A., Watson, M. L., Seldin, M. F., Clifford, K. N., Grabstein, K., Alderson, M. R. et al. (1994). Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. Cric. Shock, 44, 30-34.
54. Armitage, R. J., Tough, T. W., Macduff, B. M., Fanslow, W. C., Spriggs, M. K., Ramsdell, F. and Alderson, M. R. (1993). CD40 ligand is a T-cell growth factor. Eur. J. Immunol., 23, 2326-2331.
55. Bazzoni, F. and Beutler, B. Seminars in medicine of the Beth Israel Hospital, Boston: The tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 334, 1717-1725.
56. Younes, A., Consoli, U., Zhao, S., Snell, V., Thomas, E., Gruss, H. J., Cabanillas, F. and Andreeff, M. (1996). CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br. J. Haematol., 93, 569-571.
57. Desai-Mehta, A., Lu, L., Ramsey-Goldman, R. and Datta, S. K. (1996). Hyperexpression of CD40 ligand by B- and T-cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest., 97, 2063-2073.
58. Gauchat, J. F., Henchoz, S., Fattah, D., Mazzei, G., Aubry, J. P., Jomotte, T., Dash, L., Page, K., Solari, R., Aldebert, D. et al. (1995). CD40 ligand is functionally expressed on human eosinophils. Eur. J. Immunol., 25, 863-865.
59. Grammer, A. C., Bergman, M. C., Miura, Y., Fujita, K., Davis, L. S. and Lipsky, P. E. (1995). The CD40 ligand expressed by human B-cells costimulates B-cell responses. J. Immunol., 154, 4996-5010.
60. Griffith, T. S., Brunner, T., Fletcher, S. M., Greend, D. R. and Ferguson, T. A. (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege [see comments]. Science, 270, 1189-1192.
61. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A. and Duke, R. C. (1995). A role for CD95 ligand in preventing graft rejection (see comments). Nature, 377, 630-632.
62. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A. H. and Nagata, S. (1996). Fas ligand in human serum. Nat Med, 2, 317-322.
63. Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.-J., Broger, C., Loetscher, H. and Lesslauer, W. (1993). Crystal structure of the soluble human 55 kc TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell, 73, 431-445.
64. Rothe, M., Wong, W. C., Henzel, W. J. and Goeddel, D. V. (1995). A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell, 78, 681-692.
65. Rothe, M., Sarma, V., Dixit, V. M. and Goeddel, D. V. (1995). TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science, 269, 1424-1427.
66. Hu, H. M., O'Rourke, K., Boguski, M. S. and Dixit, V. M. (1994). A novel RING finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem., 269, 30069-30072.
67. Cheng, G. and Baltimore, D. (1996). TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation. Genes. Dev., 10, 963-973.
68. Smith, C. A., Farrah, T. and Goodwin, R. G. (1994). The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76, 959-962.
69. Chinnaiyan, A. M., O'Rourke, K., Tewari, M. and Diwit, V. M. (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81, 505-512.
70. Hsu, H., Xiong, J. and Goeddel, D. V. (1995). The TNF receptor 1-associated protein TRADD singals cell death and NF-kB activation. Cell, 81, 495-504.
71. Heller, R. A. and Kronke, M. (1994). Tumor necrosis factor receptor-mediated signaling pathways. J. Cell. Biol., 125, 5-9.
72. Rao, P., Hsu, K. C. and Chao, M. V. (1995). Upregulation of NF-kappa B-dependent gene expression mediated by the p75 tumor necrosis factor receptor. J. Interferon Cytokine Res., 15, 171-177.
73. Gruss, H. J., Ulrich, D., Dower, S. K., Herrmann, F. and Brach, M. A. (1996). Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-κB transcription factor. Blood, 87, 2443-2449.
74. McDonald, P. P., Cassatella, M. A., Bald, A., Maggi, E., Romagnani, S., Gruss, H. J. and Pizzolo, G. (1995). CD30 ligation induces nuclear factor-kappa B activation in human T-cell lines. Eur J Immunol, 25, 2870-2876.
75. Beg, A. A. and Baltimore, D. (1996). An essential role for NF-kB in preventing cell death. Science, 274, 782-784.
76. Wang, C.-Y., Mayo, M. W. and Baldwin, A. S. Jr. (1996). TNF- and Cancer Therapy-induced apoptosis: Potentiation by inhibition of NF-k B. Science, 274, 784-787.
77. Van Antwerp, D. J. Martin, S. J., Kafri, T. Green, D. R. and Verma, I. M. (1996). Suppression on TNF-induced apoptosis by NF-κB. Science, 274, 787-789.
78. Gruss, H. J., Boiani, N., Williams, D. E., Armitage, R. J., Smith, C. A. and Goodwin, R. G. (1994). Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood, 83, 2045-2056.
79. Nagata, S. (1994). Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 345, 281-287.
80. Alderson, M. R. , Armitage, R. J., Maraskovsky, E., Tough, T. W., Roux, E., Schooley, K., Ramsdell, F. and Lynch, D. H. (1993). Fas transduces activation signals in normal human T-lymphocytes. J Exp. Med., 178, 2231-2235.
81. Armitage, R. J., Maliszewski, C. R., Alderson, M. R., Grabstein, K. H., Spriggs, M. K. and Fanslow, W. C. (1993). CD40L: a multi-functional ligand. Semin. Immunol., 5, 401-412.
82. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. and Nagata, S. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 356, 314-317.
83. Allen, R. C., Armitage, R. J., Conley, M. E., Rosenblatt, H., Jenkins, N. A., Copeland, N. G., Bedell, M. A., Edelhoff, S., Disteche, C. M., Simoneaux, D. K. et al. (1993). CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome (see comments). Science, 259, 990-993.
84. Korthauer, U., Graf, D., Mages, H. W., Briere. F., Padayachee, M., Malcolm, S., Ugazio, A. G., Notarangelo, L. D., Levinsky, R. J. and Kroczek, R. A. (1993). Defective expression of T-cell CD40 ligand causes X-linked immuno-deficiency with hyper-IgM (see comments). Nature, 361, 539-541.
85. Aruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., Bajorath, J., Grosmaire, L. S., Stenkamp, R., Neubauer, M. et al. (1993). The CD40 ligand, gp39, is defective in activated T-cells from patients with X-linked hyper-IgM syndrome. Cell, 72, 291-300.
86. Nadali, G., Vinante, F., Ambrosetti, A., Todeschini, G., Veneri, D., Zanotti, R., Meneghini, V., Ricetti, M. M., Benedetti, F., Vassanelli, A. et al. (1994). Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J. Clin. Oncol., 12, 793-797.
87. Cause, A., Pohl, C., Tschiersch, A., Da Costa, L., Jung, W., Diehl, V., Hasenclever, D. and Pfreundschuh, M. (1991). Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood, 77, 1983-1988.
88. Hummel, M., Ziemann, K., Lammert, H., Pileri, S., Sabattini, E. and Stein, H. (1995). Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N. Engl. J. Med., 333, 901-906.
89. Davis, T. H., Morton, C. C., Miller-Cassman, R., Balk, S. P. and Kadin, M. E. (1992). Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N. Engl. J. Med., 326, 1115-1122.
90. Munro, J. M., Freedman, A. S., Aster, J. C., Gribben, J. G., Lee, N. C., Rhynhart, K. K., Banchereau, J. and Nadler, L. M. (1994). In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood, 83, 793-798.
91. Delabie, J., Ceuppens, J. L., Vandenberghe, P., de Boer, M., Coorevits, L. and De Wolf-Peeters, C. (1993). The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkjn's disease-derived cell lines. Blood, 82, 2845-2852.
92. Hsu, S. M. and Hsu, P. L. (1990). Lymphocyte functional antigens stabilize agglutination between Reed-Sternberg cells and T-cells, but are not responsible for homotypic binding of Hodgkin's Reed-Sternberg cells. Am. J. Pathol., 137, 563-574.
93. Brousset, P., Benharroch, D., Krajewski, S., Laurent, G., Meggetto, F., Rigal-Huguet, F., Gopas, J., Prinsloo, I., Pris, J., Delsol, G., Reed, J. C. and Schlaifer, D. (1996). Frequent expression of the cell death-inducing gene Bax in Reed-Slernberg cells of Hodgkin's disease. Blood, 78, 2470-2475.
94. Schwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H. H., Schaadt, M. and Diehl, V. (1982). Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature, 299, 65-67.
95. Stein, H., Gerdes, J., Schwab, U., Lemke, H., Mason, D. Y., Ziegler, A., Schienle, W. and Diehl, V. (1982). Identification of Hodgkin's and Sternberg-Reed cells as a unique cell type derived from a newly-detected small cell population. Int. J. Cancer, 30, 445-459.
96. Haluska, F. G., Brufsky, A. M. and Canellos, G. P. (1994). The cellular biology of the Reed-Sternberg cell. Blood, 84, 1005-1019.
97. Gruss, H. J., Brach, M. A., Drexler, H. G., Bonifer, R., Mertelsmann, R. H. and Herrmann, F. (1992). Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res., 52, 3353-3360.
98. Kurzrock, R., Redman, J., Cabanillas, F., Jones, D., Rothberg, J. and Talpaz, M. (1993). Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res., 53, 2118-2122.
99. Stein, H., Mason, D. Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H. et al. (1985). The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood, 66, 848-858.
100. Andreesen, R., Osterholz, J., Lohr, G. W. and Bross, K. J. (1984). A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloaclivated T (helperl) lymphoblasts. Blood, 63, 1299-1302.
101. Gruss, H. J., Pinto, A., Gloghini, A., Wehnes, E., Wright, B., Boiani, N., Aldinucci, D., Gattei, V., Zagonel, V., Smith, C. A., Kadin, M. E., Shilling, C., Goodwin, R. G., Herrmann, F. and Carbone, A. (1996). CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am. J. Pathol, 149, 469-481.
102. + T-cells. J. Immunol., 151, 2380-2389.
103. Cambiaggi, A., Cantoni, C., Marciano, S., De Totero, D., Pileri, S., Tazzari, P. L., Stein, H. and Ferrini, S. (1993). Cultured human NK cells express the Ki-1/CD30 antigen. Br. J. Haematol., 85, 270-276.
104. Nawrocki, J. F., Kirsten, E. S. and Fisher, R. I. (1988). Biochemical and structural properties of a Hodgkin's disease related membrane protein. J. Immunol., 141, 672-680.
105. Fonatsch, C., Latza, U., Durkop, H., Rieder, H. and Stein, H. (1992). Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics, 14, 825-826.
106. Gruss, H. J., Da Silva, N., Hu, Z. B., Uphoff, C. C., Goodwin, R. G. and Drexler, H. G. (1994). Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia, 8, 2083-2094.
107. Pizzolo, G., Vinante, F., Chilosi, M., Dallenbach, F., Josimovic-Alasevic, O. and Diamantstein, T. (1990). Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol., 75, 282-284.
108. Jumper, M. D., Nishioka, Y., Davis, L. S., Lipsky, P. E. and Meek, K. (1995). Regulation of human B-cell function by recombinant CD40 ligand and other TNF-related ligands. J. Immunol., 155, 2369-2378.
109. Bowen, M. A., Olsen, K. J., Cheng, L., Avila, D. and Podack, E. R. (1993). Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J. Immunol., 151, 5896-5906.
110. Amakawa, R., Hakem, A., Kundig, T. M., Matsuyama, T., Simard, J. J., Timms, E., Wakeham, A., Mittruecker, H. W., Griesser, H., Takimoto, H., Schmits, R., Shahinian, A., Ohashi, P., Penninger, J. M. and Mak, T. W. (1996). Impaired negative selection of T-cells in Hodgkin's disease antigen CD30-deficient mice. Cell, 84, 551-562.
111. Gruss, H. J., Scheffrahn, I., Huebinger, G., Duyster, J. and Herrmann, F. (1996). The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia. 10, 829-835.
112. Gruss, H. J., Ulrich, D., Braddy, S., Armitage, R. J. and Dower, S. K. (1995). Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur. J. Immunol., 25, 2083-2089.
113. + T-cells producing Th2-type cytokines. FASEB J., 9, 81-86.
114. + lymphoma. Haematologica, 80, 357-366.
115. Del Prete, G., Maggi, E., Pizzolo, G. and Romagnani, S (1995). CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today, 16, 76-80.
116. Gruss, H. J., Hirschstein, D., Wright, B., Ulrich, D., Caligiuri, M. A., Barcos, M., Strockbine, L., Armitage, R. J. and Dower, S. K. (1994). Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood, 84, 2305-2314.
117. Xerri, L., Carbuccia, N., Parc, P., Hassoun, J. and Birg, F. (1995). Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology, 27, 235-241.
118. Owen-Schaub, L. B., Meterissian, S. and Ford, R. J. (1993). Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J. Immunother., 14, 234-241.
119. Nagata, S. and Golstein, P. (1995). The Fas death factor. Science, 267, 1449-1456.
120. + T helper type 2 and type 0 cells by T helper type 1 cells via Fas/Fas-ligand interaction. Eur. J. Immunol., 25, 2679-2685.
121. Ramsdell, F., Seaman, M. S., Miller, R. E., Picha, K. S., Kennedy, M. K. and Lynch, D. H. (1994). Differential ability of Th1 and Th2 T-cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol., 6, 1545-1553.
122. Carbone, A., Gloghini, A., Gattei, V., Aldinucci, D., Degan, M., De Paoli, P., Zagonel, V. and Pinto, A. (1995). Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines, Blood, 85, 780-789.
123. O'Grady, J. T., Stewart, S., Lowrey, J., Howie, S. E. and Krajewski, A. S. (1994). CD40 expression in Hodgkin's disease [see comments]. Am. J. Pathol., 144, 21-26.
124. Renner, C., Bauer, S., Sahin, U., Jung, W., van Lier, R., Jacobs, G., Held, G. and Pfreundschuh, M. (1996). Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T-cells: the role of human T-cell subsets in a preclinical model. Blood, 87, 2930.